| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2006;81:314-321
© 2006 The Society of Thoracic Surgeons
a Division of Thoracic Surgery, McMaster University/St. Joseph's Hospital, Hamilton, Ontario
b Division of Thoracic Surgery, University of Western Ontario, London, Ontario
c Division of Thoracic Surgery, University of Manitoba, Winnipeg, Manitoba
d Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Accepted for publication July 18, 2005.
* Address correspondence to Dr Miller, McMaster University, 50 Charlton Avenue East, Hamilton, Ontario, Canada, L8N 4A6 (Email: jmiller{at}mcmaster.ca).
Presented at the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 24–26, 2005.
BACKGROUND: We present a summary report evaluating the efficacy of lung volume reduction surgery (LVRS) in patients with advanced emphysema in the Canadian setting.
METHODS: Quality of Life measures assessed the efficacy of adding LVRS to best medical care including rehabilitation in this blinded randomized multicentered controlled trial with 2 years of follow-up. Health utility and quality-adjusted life years (QALY) were outcomes central to our economic assessment.
RESULTS: None of the 32 patients randomized to the LVRS arm or 30 patients in the best medical care (BMC) arm crossed-over and no patients were lost to follow-up. Overall surgical mortality was 16% at 2 years while the overall medical mortality was 13% (p = 0.914). There were no 30-day postoperative deaths but 2 deaths (6%) occurred within 90 days of randomization. Surgery reduced the residual volume measured at 6 months by 23% (5,385 mL to 4,322 mL, p = 0.007). There was an increase in forced expiratory volume in 1 second (FEV1) of 30% (265 mL, p = 0.013) from baseline, an improvement in the six minute walk test (6MWT) of 78 meters (p = 0.045), and an increase in Health Utility Index 3 (HUI3) which peaked at 6 months with a difference of 0.16 (p = 0.129). There was a gain in QALYs of 0.21 (p = 0.19) in the LVRS-arm over the BMC-arm. The LVRS costs an additional $28,119 Canadian dollars (CAD) compared with BMC or $133,900/QALY gained.
CONCLUSIONS: The addition of LVRS to best medical care including pulmonary rehabilitation improves pulmonary function, exercise activity, and quality of life in selected patients with advanced emphysema. Cost is high but in keeping with other treatment modalities currently available.
This article has been cited by other articles:
|
|
 |
|
  S. D. Ramsey, S. D. Sullivan, and R. M. Kaplan Cost-Effectiveness of Lung Volume Reduction Surgery Proceedings of the ATS, May 1, 2008; 5(4): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tacconi, E. Pompeo, D. Forcella, M. Marino, D. Varvaras, and T. C. Mineo Lung Volume Reduction Reoperations Ann. Thorac. Surg., April 1, 2008; 85(4): 1171 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pompeo and T. C. Mineo Two-Year Improvement in Multidimensional Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index After Nonresectional Lung Volume Reduction Surgery in Awake Patients Ann. Thorac. Surg., December 1, 2007; 84(6): 1862 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Trotta, A. V. Stolin, M. B. Williams, S. B. Gay, A. S. Brody, and T. A. Altes Characterization of the Relation Between CT Technical Parameters and Accuracy of Quantification of Lung Attenuation on Quantitative Chest CT Am. J. Roentgenol., June 1, 2007; 188(6): 1683 - 1690. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
